Immatics N.V. Announces Significant Public Offering
Immatics N.V. (NASDAQ: IMTX) has taken a significant step in its journey to advance cancer treatment by announcing the pricing for its public offering of 16,250,000 ordinary shares, with each share priced at $9.25. This strategic move is expected to result in gross proceeds of approximately $150 million, critical for funding their innovative cancer immunotherapies.
Details of the Offering
The company plans to close the offering shortly, pending customary conditions. Additionally, Immatics has provided underwriters with a 30-day option to purchase up to 2,437,500 additional shares, allowing for potential future expansion based on market demand.
Role of the Underwriters
Leading the charge in this public offering are Jefferies, BofA Securities, and Leerink Partners, acting as joint book-running managers. Their involvement underscores the confidence placed in Immatics' growth trajectory and its pioneering work in cancer immunotherapy.
Investor Information and Additional Resources
Investors interested in obtaining the final prospectus can do so through designated channels, ensuring transparency and accessibility to all relevant offering documents.
About Immatics
Immatics is dedicated to transforming cancer treatment through T cell-redirecting immunotherapies. The company’s unique approach involves discovering precise targets and developing tailored T cell receptors, enhancing the effectiveness of treatment options available to patients. Their pipeline includes promising Adoptive Cell Therapies and TCR Bispecifics, backed by partnerships with industry leaders.
Looking Ahead
Immatics' robust strategies and innovations position it well within the biopharmaceutical landscape. As research and development continue, the company aims to unlock new pathways for patients battling cancer, embodying their commitment to improving outcomes through science.
Frequently Asked Questions
What is the total amount raised from the public offering?
The public offering is expected to raise approximately $150 million before deducting underwriting discounts and other expenses.
Who are the underwriters for this offering?
The underwriters for Immatics' offering are Jefferies, BofA Securities, and Leerink Partners.
When is the expected closing date for the offering?
The offering is expected to close soon, subject to customary closing conditions.
What are the future prospects for Immatics after this offering?
This capital raise will facilitate Immatics’ continuing research and development efforts in cancer immunotherapy, supporting their innovative projects.
How can investors access the final prospectus?
Investors can obtain the final prospectus supplement and accompanying prospectus free of charge from the underwriters involved in the offering.
